Patients nix genetic tests due to cost, says study

Pennsylvania researchers have discovered that a sizable percentage of patients potentially at risk for cancer would turn down testing to uncover genes linked to the disease. While their study named cost as the most likely reason, a number of other factors could influence individuals to nix the tests.

View the original article here: Patients Nix Genetic Tests Due to Cost: Study

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Deaths from COVID-19 are far higher than reported estimates

Infographic: Deaths from COVID-19 are far higher than reported estimates

More than 2.8 million people have lost their lives due to the pandemic, according to a Wall Street Journal analysis ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend